Form 8-K - Current report:
SEC Accession No. 0001493152-24-007506
Filing Date
2024-02-22
Accepted
2024-02-22 09:30:16
Documents
26
Period of Report
2024-02-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 37838
2 ex99-1.htm EX-99.1 11690
3 ex99-1_001.jpg GRAPHIC 236011
4 ex99-1_002.jpg GRAPHIC 247656
5 ex99-1_003.jpg GRAPHIC 426241
6 ex99-1_004.jpg GRAPHIC 214930
7 ex99-1_005.jpg GRAPHIC 149930
8 ex99-1_006.jpg GRAPHIC 322254
9 ex99-1_007.jpg GRAPHIC 158536
10 ex99-1_008.jpg GRAPHIC 67574
11 ex99-1_009.jpg GRAPHIC 206310
12 ex99-1_010.jpg GRAPHIC 144486
13 ex99-1_011.jpg GRAPHIC 150971
  Complete submission text file 0001493152-24-007506.txt   3421175

Data Files

Seq Description Document Type Size
14 XBRL SCHEMA FILE pvct-20240222.xsd EX-101.SCH 3027
15 XBRL LABEL FILE pvct-20240222_lab.xml EX-101.LAB 34240
16 XBRL PRESENTATION FILE pvct-20240222_pre.xml EX-101.PRE 22367
27 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3303
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 24662575
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)